Dexcom CONNECT Study Validates CGM Effectiveness for Type 2 Diabetes

Key Facts

1The New England Journal of Medicine published CONNECT study results showing a 1.6% A1C reduction for Dexcom G7 users.

DexCom announced the publication of its CONNECT clinical trial results in the New England Journal of Medicine, proving the effectiveness of continuous glucose monitoring in reducing blood sugar levels. The data showed a 1.6% reduction in A1C levels for Type 2 diabetes patients not using insulin when utilizing the Dexcom G7 device.

The findings aim to redefine the standard of care and expand the addressable market for CGM technology to a broader demographic of diabetic patients. Regarding equity performance, DXCM closed at $85.06 on October 13, 2026, having traded between a session low of $84.49 and a high of $86.6.